George Vande Woude
Overview
Explore the profile of George Vande Woude including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Knudsen B, Vande Woude G
Curr Opin Genet Dev
. 2008 Apr;
18(1):87-96.
PMID: 18406132
The receptor tyrosine kinase, c-MET and its ligand hepatocyte growth factor/scatter factor (HGF/SF) have become leading candidates for targeted cancer therapies. Inappropriate c-MET signaling through autocrine, paracrine, amplification, and mutational...
12.
Rouleau C, Menon K, Boutin P, Guyre C, Yoshida H, Kataoka S, et al.
Int J Oncol
. 2008 Mar;
32(4):739-48.
PMID: 18360701
Two of the three components of anthrax toxin, protective antigen (PA) and lethal factor (LF), together known as lethal toxin (LeTx), reportedly show anti-tumor activity in melanoma in vitro and...
13.
Tolbert W, Daugherty J, Gao C, Xie Q, Miranti C, Gherardi E, et al.
Proc Natl Acad Sci U S A
. 2007 Sep;
104(37):14592-7.
PMID: 17804794
Hepatocyte growth factor (HGF) activates the Met receptor tyrosine kinase by binding and promoting receptor dimerization. Here we describe a mechanistic basis for designing Met antagonists based on NK1, a...
14.
Duesbery N, Vande Woude G
Sci STKE
. 2006 Mar;
2006(328):pe15.
PMID: 16569817
The small guanosine triphosphatase KRAS and the protein kinases BRAF, which is a mitogen-activated protein kinase kinase kinase (MAPKKK), and mitogen-activated protein kinase kinase 1 and 2 (MAPKK1/2, also known...
15.
Ren Y, Cao B, Law S, Xie Y, Lee P, Cheung L, et al.
Clin Cancer Res
. 2005 Sep;
11(17):6190-7.
PMID: 16144920
Purpose: Hepatocyte growth factor/scatter factor (HGF/SF) and its receptor, c-Met, play important roles in tumor development and progression. In this study, we measured the serum HGF levels in patients with...
16.
Shen Y, Xie Q, Norberg M, Sausville E, Vande Woude G, Wenkert D
Bioorg Med Chem
. 2005 Jun;
13(16):4960-71.
PMID: 15978816
Ansamycins, including geldanamycin and the derivative 17-allylamino-17-demethoxygeldanamycin, and radicicol are known for their ability to tightly bind to the ATP-binding site of the amino-terminal domain region of heat shock protein...
17.
Graveel C, Su Y, Koeman J, Wang L, Tessarollo L, Fiscella M, et al.
Proc Natl Acad Sci U S A
. 2004 Nov;
101(49):17198-203.
PMID: 15557554
Tyrosine kinase-activating mutations in Met have been observed in hereditary papillary renal carcinomas as well as in other cancers. These mutations have been examined in several in vitro systems, where...
18.
Fan J, Tam P, Vande Woude G, Ren Y
Proc Natl Acad Sci U S A
. 2004 Jan;
101(5):1135-40.
PMID: 14739336
The quantitative comparison of two or more microarrays can reveal, for example, the distinct patterns of gene expression that define different cellular phenotypes or the genes that are induced in...
19.
Hammond D, Carter S, McCullough J, Urbe S, Vande Woude G, Clague M
Mol Biol Cell
. 2003 Apr;
14(4):1346-54.
PMID: 12686592
Proteasomal activity is required for Met receptor degradation after acute stimulation with hepatocyte growth factor (HGF). Inhibition of proteasomal activity with lactacystin leads to a block in the endocytic trafficking...
20.
Hay R, Cao B, Tsarfaty I, Tsarfaty G, Resau J, Vande Woude G
J Cell Biochem Suppl
. 2003 Jan;
39:184-93.
PMID: 12552618
The availability of a test to assess the likelihood that a given tumor will invade or metastasize would be a useful development in clinical oncology. We propose that multimodality imaging...